Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma

This study is testing whether targeted radiation therapy (SBRT — precise high-dose radiation to specific spots) can help people with metastatic melanoma whose cancer is progressing in just a few locations while still responding to immunotherapy or BRAF-targeted drugs everywhere else. This approach is called treating 'oligoprogression.' **You may be eligible if...** - You are 18 or older with confirmed metastatic melanoma - You are currently being treated with first-line immunotherapy or BRAF inhibitors - Your cancer is progressing in up to 10 specific spots outside the brain, while remaining stable or responding elsewhere - All progressing spots can be safely targeted with precision radiation (SBRT) - You are in reasonably good physical condition (ECOG 0-2) **You may NOT be eligible if...** - You have more than 10 sites of progression outside the brain - You are pregnant - You have cancer spreading through the lining of the brain (leptomeningeal disease) - You have a medical condition that makes radiation unsafe (e.g., scleroderma, ataxia-telangiectasia) - Prior radiation in the same area prevents safe re-treatment Talk to your doctor to see if this trial is right for you.